Results 1 to 10 of about 5,941 (192)

Current Trends in Treatment for Acid-Dependent Diseases: Clinical Efficacy and Safety of Rabeprazole [PDF]

Российский журнал гастроэнтерологии, гепатологии, колопроктологии, 2021
Aim. A comparative review of the rabeprazole properties vs. other PPIs, its efficacy and safety in treatment for aciddependent diseases.Key points. Rabeprazole provides a rapid proton pump blockade in parietal cells due to its high dissociation constant (
O. D. Lopina, B. K. Nurgalieva, T. L. Lapina   +2 more
doaj   +2 more sources

EFFECTIVENESS OF RABEPRAZOLE FOR THE TREATMENT OF ACID-RELATED DISEASES [PDF]

Медицинский совет, 2017
The analysis of modern data about the effectiveness of rabeprazole in the treatment of acid-related diseases is performed. The European Consensus Maastricht 5 recommends a preferred use of rabeprazole in the schemes of eradication of Helicobacter pylori.
V. V. Tsukanov, E. V. Kasparov, A. V. Vasyutin, Y. L. Tonkikh, O. V. Peretyatko   +4 more
doaj   +2 more sources

Repurposing of rabeprazole as an anti-Trypanosoma cruzi drug that targets cellular triosephosphate isomerase

Journal of Enzyme Inhibition and Medicinal Chemistry, 2023
Trypanosoma cruzi is the causative agent of American trypanosomiasis, which mainly affects populations in Latin America. Benznidazole is used to control the disease, with severe effects in patients receiving this chemotherapy.
Itzhel García-Torres, Ignacio De la Mora-De la Mora, Gabriel López-Velázquez, Nallely Cabrera, Luis Antonio Flores-López, Ingeborg Becker, Juliana Herrera-López, Roberto Hernández, Ruy Pérez-Montfort, Sergio Enríquez-Flores   +9 more
doaj   +2 more sources

Exploring Differences in Pharmacometrics of Rabeprazole between Genders via Population Pharmacokinetic–Pharmacodynamic Modeling

Biomedicines, 2023
Rabeprazole is a proton pump inhibitor that inhibits gastric acid production and increases gastric pH; it is widely used clinically as a treatment option for gastritis and gastric ulcers.
Seung-Hyun Jeong, Ji-Hun Jang, Yong-Bok Lee   +2 more
doaj   +2 more sources

Pharmacokinetics and pharmacodynamics of injectable dex-rabrazole for healthy people

Di-san junyi daxue xuebao, 2021
Objective To study the pharmacokinetic and pharmacodynamic characteristics of dex-rabeprazole for injection at different doses in healthy subjects and to evaluate its safety.
YU Mingjie, SUN Fengjun, XIONG Lirong, CHENG Lin, DAI Qin, LI Xiaochuan   +5 more
doaj   +1 more source

Effect of Rabeprazole and Rebamipide in the Treatment of Upper Gastrointestinal Hemorrhage Associated with Dual Antiplatelet Therapy in Elderly Patients with Coronary Heart Disease

Clinical and Applied Thrombosis/Hemostasis, 2022
To investigate the therapeutic effect of rabeprazole and rebamipide on patient age over 60 with dual antiplatelet therapy (DAPT)–related upper gastrointestinal hemorrhage following percutaneous coronary intervention (PCI).
Rong-Jie Jia MD, Xiao-Peng Wang MM, Zhen-Hua Zhang MM, Hai-Hong Cui MD, Rui Qin MM, Da-Yong Du MM, Yang Liu MD   +6 more
doaj   +1 more source

Supplement With Calcium or Alendronate Suppresses Osteopenia Due to Long Term Rabeprazole Treatment in Female Mice: Influence on Bone TRAP and Osteopontin Levels

Frontiers in Pharmacology, 2020
Background and PurposeRabeprazole, a proton pump inhibitor (PPIs) is much endorsed to patients with increased gastric acidity. PPIs were accused to have osteoporotic effects on patients who chronically use them. The point of the current investigation was
Aly A.M. Shaalan, Aly A.M. Shaalan, Mohamed El-Sherbiny, Mohamed El-Sherbiny, Taghrid B. El-Abaseri, Mohamed Z. Shoaeir, Tarek M. Abdel-Aziz, Magda I. Mohamed, Sawsan A. Zaitone, Sawsan A. Zaitone, Hala M. F. Mohammad, Hala M. F. Mohammad   +11 more
doaj   +1 more source

Efficacy and Tolerability of 14-Day Tegoprazan- versus Rabeprazole-Based Triple Therapy for Eradication of Helicobacter pylori: A Real-World Evidence Study

Gut and Liver, 2023
Background/Aims: Tegoprazan, a new, fast, and strong potassium-competitive acid blocker, has been approved for the treatment of gastric acid-related diseases in Korea. However, real-world clinical data regarding this drug are scarce.
Yoon Suk Jung, Sunyong Kim, Hyun-Young Kim, Seung Jae Noh, Jung Ho Park, Chong Il Sohn, Chan Hyuk Park   +6 more
doaj   +1 more source

Effect and safety of anaprazole in the treatment of duodenal ulcers: a randomized, rabeprazole-controlled, phase III non-inferiority study

Chinese Medical Journal, 2022
. Background:. The pharmacokinetic and clinical behaviors of many proton pump inhibitors (PPIs) in peptic ulcer treatment are altered by CYP2C19 genetic polymorphisms.
Huiyun Zhu, Xue Pan, Li Zhang, Hongxin Sun, Huizhen Fan, Zhongwei Pan, Caibin Huang, Zhenwang Shi, Jin Ding, Qi Wang, Yiqi Du, Nonghua Lyu, Zhaoshen Li, Yuanyuan Ji   +13 more
doaj   +1 more source

Rabeprazole inhibits inflammatory reaction by inhibition of cell pyroptosis in gastric epithelial cells

BMC Pharmacology and Toxicology, 2021
Background Helicobacter pylori (H. pylori) is a common pathogen in development of peptic ulcers with pyroptosis. Rabeprazole, a critical component of standard triple therapy, has been widely used as the first-line regimen for H.
Jing Xie, Long Fan, Liya Xiong, Peiyu Chen, Hongli Wang, Huan Chen, Junhong Zhao, Zhaohui Xu, Lanlan Geng, Wanfu Xu, Sitang Gong   +10 more
doaj   +1 more source